title: C-terminal anchoring of a peptide to class II MHC via the P10 residue is compatible with a peptide bulge.
abstract: The binding of antigenic peptide to class II MHC is mediated by hydrogen bonds between the MHC and the peptide, by salt bridges, and by hydrophobic interactions. The latter are confined to a number of deeper pockets within the peptide binding groove, and peptide side chains that interact with these pockets are referred to as anchor residues. T cell recognition involves solvent-accessible peptide residues along with minor changes in MHC helical pitch induced by the anchor residues. In class I MHC there is an added level of epitope complexity that results from binding of longer peptides that bulge out into the solvent-accessible, T cell contact area. Unlike class I MHC, class II MHC does not bind peptides of discrete length, and the possibility of peptide bulging has not been clearly addressed. A peptide derived from position 24-37 of integrin beta(3) can either bind or not bind to the class II MHC molecule HLA DRB3*0101 based on a polymorphism at the P9 anchor. We show that the loss of binding can be compensated by changes at the P10 position. We propose that this could be an example of a class II peptide bulge. Although not as efficient as P9 anchoring, the use of P10 as an anchor adds another possible mechanism by which T cell epitopes can be generated in the class II presentation system.
authors.affiliation: Blood Research Institute, Blood Center of Southeastern Wisconsin, Milwaukee, WI 53201-2178, USA.
authors.forename: Maryam
authors.initials: M
authors.lastname: Yassai
authors.forename: Amin
authors.initials: A
authors.lastname: Afsari
authors.forename: Jason
authors.initials: J
authors.lastname: Garlie
authors.forename: Jack
authors.initials: J
authors.lastname: Gorski
mesh_terms: D019943:Amino Acid Substitution / Q000276:immunology; D000596:Amino Acids / Q000737:chemistry* / Q000378:metabolism*; D015703:Antigens, CD / Q000737:chemistry / Q000378:metabolism; D001667:Binding, Competitive / Q000276:immunology; D005998:Glycine / Q000378:metabolism; D006684:HLA-DR Antigens / Q000378:metabolism*; D059826:HLA-DRB3 Chains; D006801:Humans; D039661:Integrin beta3; D007930:Leucine / Q000378:metabolism; D010446:Peptide Fragments / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism*; D010980:Platelet Membrane Glycoproteins / Q000737:chemistry / Q000378:metabolism; D011392:Proline / Q000378:metabolism; D011485:Protein Binding / Q000276:immunology; D011487:Protein Conformation; D013329:Structure-Activity Relationship
chemical_list: D000596:Amino Acids; D015703:Antigens, CD; D006684:HLA-DR Antigens; D059826:HLA-DRB3 Chains; D039661:Integrin beta3; D010446:Peptide Fragments; D010980:Platelet Membrane Glycoproteins; D011392:Proline; D007930:Leucine; D005998:Glycine